| Thomas Earl Guyden, MD | |
|
6161 W Charleston Blvd, Las Vegas, NV 89146 | |
| (702) 486-6091 | |
| (702) 486-0411 |
| Full Name | Thomas Earl Guyden |
|---|---|
| Gender | Male |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | 6161 W Charleston Blvd, Las Vegas, Nevada |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1528070786 | NPI | - | NPPES |
| 100505872 | Medicaid | NV |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 10820 (Nevada) | Primary |
| Entity Name | State Of Nevada |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760572010 PECOS PAC ID: 9234022153 Enrollment ID: O20040212000160 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Associated Press reports on efforts to provide culturally appropriate care for Native Americans, by focusing on the simultaneous work of medical doctors such as Joachim Chino, a Navajo-Acoma, and traditional healers such as Navajo medicine man David Begay.
Researchers at Case Western Reserve University School of Dental Medicine have unraveled one of the mysteries of how a small group of immune cells work: That some inflammation-fighting immune cells may actually convert into cells that trigger disease.
Forest Laboratories, Inc. (NYSE: FRX) and Glenmark Pharmaceuticals S.A. (Switzerland), a wholly owned subsidiary of Glenmark Pharmaceuticals India (GPL) today announced top-line results from a Phase IIb dose range-finding study of oglemilast in patients with Chronic Obstructive Pulmonary Disease (COPD). Once-daily treatment with oglemilast did not show a statistically meaningful increase from baseline compared to placebo in the primary endpoint trough FEV1, a measure of pulmonary function that is decreased in patients with COPD. Oglemilast was well tolerated at all doses studied.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Thomas Earl Guyden, MD 1681 E Flamingo Rd, #2, Las Vegas, NV 89119-5274 Ph: (702) 650-0633 | Thomas Earl Guyden, MD 6161 W Charleston Blvd, Las Vegas, NV 89146 Ph: (702) 486-6091 |
News Archive
Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlowRx Pharmacy Workflow Manager products. The Baxa IntelliSource(TM) program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.
The Associated Press reports on efforts to provide culturally appropriate care for Native Americans, by focusing on the simultaneous work of medical doctors such as Joachim Chino, a Navajo-Acoma, and traditional healers such as Navajo medicine man David Begay.
Researchers at Case Western Reserve University School of Dental Medicine have unraveled one of the mysteries of how a small group of immune cells work: That some inflammation-fighting immune cells may actually convert into cells that trigger disease.
Forest Laboratories, Inc. (NYSE: FRX) and Glenmark Pharmaceuticals S.A. (Switzerland), a wholly owned subsidiary of Glenmark Pharmaceuticals India (GPL) today announced top-line results from a Phase IIb dose range-finding study of oglemilast in patients with Chronic Obstructive Pulmonary Disease (COPD). Once-daily treatment with oglemilast did not show a statistically meaningful increase from baseline compared to placebo in the primary endpoint trough FEV1, a measure of pulmonary function that is decreased in patients with COPD. Oglemilast was well tolerated at all doses studied.
› Verified 6 days ago
Dr. Ejine Okoroafor, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 5440 W Sahara Ave, Suite 202, Las Vegas, NV 89146 Phone: 914-426-7774 | |
Dr. Garet Jefferson Zaugg, D.O. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2020 Wellness Way Ste 300, Las Vegas, NV 89106 Phone: 702-432-2233 Fax: 702-800-5456 | |
Dr. Muhammed A Hyder, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2465 E Twain Ave, Las Vegas, NV 89121 Phone: 702-789-6201 Fax: 304-522-0686 | |
Dr. Krista Linn Pinard, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3016 W Charleston Blvd Ste 150, Las Vegas, NV 89102 Phone: 702-790-2701 | |
Gobinder S. Chopra, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 6410 Medical Center St Ste A100, Las Vegas, NV 89148 Phone: 702-796-8500 Fax: 702-796-8502 | |
Eden Santiago Lee, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3014 W Charleston Blvd Ste 130, Las Vegas, NV 89102 Phone: 702-671-6475 Fax: 702-671-6440 | |
John Reitano, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 501 S Rancho Dr, Ste I62, Las Vegas, NV 89106 Phone: 702-897-7250 Fax: 702-706-4838 |